Zaleplon improves sleep without producing rebound effects in outpatients with insomnia
The DOI matches its Crossref record.
Abstract
The efficacy and safety of three doses of zaleplon, a novel non-benzodiazepine hypnotic, were compared with those of placebo in outpatients with insomnia in this 4-week study, using zolpidem 10 mg as active comparator. Postsleep questionnaires were used to determine treatment effects on the patient's perception of sleep, as well as any development of pharmacological tolerance during therapy or rebound insomnia or withdrawal symptoms upon discontinuation of therapy. During week 1, sleep latency was significantly shorter with zaleplon 5, 10, and 20 mg compared to placebo. The significant decrease in sleep latency persisted through week 4 with zaleplon 20 mg, and was again evident with zaleplon 10 mg at week 3. Zaleplon 20 mg also had significant effects on sleep duration, number of awakenings, and sleep quality compared to placebo. No pharmacological tolerance developed during treatment with zaleplon and there were no indications of rebound insomnia or withdrawal symptoms after treatment discontinuation. Zolpidem 10 mg had significant effects on sleep latency, sleep duration, and sleep quality compared to placebo. However, a significantly greater incidence of withdrawal symptoms and a suggestion of sleep difficulty after treatment discontinuation (rebound insomnia) for all sleep measures was seen with zolpidem compared to placebo. There was no significant difference in the frequency of adverse events with active treatment compared to placebo. These results show that zaleplon provides effective treatment of insomnia with a favourable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., Denberg, T. D., & for the Clinical Guidelines Committee of the American College of Physicians* (2016) · Annals of Internal Medicine · doi:10.7326/m15-2175 · Cited by 1,965
“Zaleplon did not improve total sleep time in the general population (low-quality evidence) (56, 57).”
BackgroundSateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6470 · Cited by 1,519
Zolpidem: A Review of Its Use in the Management of Insomnia
Swainston Harrison, T., & Keating, G. M. (2005) · CNS Drugs · doi:10.2165/00023210-200519010-00008 · Cited by 323
Fatigue Countermeasures in Aviation
Caldwell, J. A., Mallis, M. M., Caldwell, J. L., Paul, M. A., Miller, J. C., & Neri, D. F. (2009) · Aviation, Space, and Environmental Medicine · doi:10.3357/asem.2435.2009 · Cited by 295
Zaleplon: A Review of its Use in the Treatment of Insomnia
Dooley, M., & Plosker, G. L. (2000) · Drugs · doi:10.2165/00003495-200060020-00014 · Cited by 287
Metadata
- Authors
- Fry, J., Scharf, M., Mangano, R., & Fujimori, M.
- Venue
- International Clinical Psychopharmacology
- Published
- 2000-05
- Volume
- 15
- Issue
- 3
- Pages
- 141-152
- ISSN
- 0268-1315 (ISSN-L)
- OpenAlex
- W2010534854
- Cited by
- 93
- References
- 0
- FWCI
- 7.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. https://app.cochat.ai/papers/10.1097/00004850-200015030-00003
- The paper
- Fry, J., Scharf, M., Mangano, R., & Fujimori, M. (2000). Zaleplon improves sleep without producing rebound effects in outpatients with insomnia. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200015030-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.